Beta Bionics, Inc. (BBNX)
BBNX Stock Price Chart
Explore Beta Bionics, Inc. interactive price chart. Choose custom timeframes to analyze BBNX price movements and trends.
BBNX Company Profile
Discover essential business fundamentals and corporate details for Beta Bionics, Inc. (BBNX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Equipment & Services
IPO Date
30 Jan 2025
Employees
352.00
Website
https://www.betabionics.comCEO
Sean T. Saint
Description
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
BBNX Financial Timeline
Browse a chronological timeline of Beta Bionics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Jul 2026
EPS estimate is -$0.62, while revenue estimate is $31.44m.
Earnings released on 21 Apr 2026
EPS came in at -$0.49 surpassing the estimated -$0.53 by +7.55%, while revenue for the quarter reached $27.63m , beating expectations by +2.52%.
Earnings released on 17 Feb 2026
EPS came in at -$0.30 surpassing the estimated -$0.42 by +28.57%, while revenue for the quarter reached $32.12m , beating expectations by +5.69%.
Earnings released on 28 Oct 2025
EPS came in at -$0.33 surpassing the estimated -$0.45 by +26.67%, while revenue for the quarter reached $27.25m , missing expectations by -5.74%.
Earnings released on 29 Jul 2025
EPS came in at -$0.39 surpassing the estimated -$0.51 by +23.53%, while revenue for the quarter reached $23.24m , beating expectations by +6.10%.
Earnings released on 6 May 2025
EPS came in at -$0.52 falling short of the estimated -$0.51 by -1.96%, while revenue for the quarter reached $17.64m , missing expectations by -10.40%.
Earnings released on 25 Mar 2025
EPS came in at -$1.82 falling short of the estimated -$0.42 by -333.33%, while revenue for the quarter reached $20.44m , beating expectations by +26.57%.
Earnings released on 31 Jan 2025
EPS came in at -$1.55 , while revenue for the quarter reached $16.70m .
Earnings released on 31 Dec 2023
EPS came in at -$3.13 , while revenue for the quarter reached $8.35m .
Earnings released on 30 Sept 2023
EPS came in at -$1.71 , while revenue for the quarter reached $3.09m .
BBNX Stock Performance
Access detailed BBNX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
